Meet David Reese: Leading Amgen's Innovative Treatments

Who is David Reese, and what is his connection to Amgen?

David Reese is a highly accomplished scientist and business leader who has made significant contributions to the biotechnology industry, particularly in the field of protein therapeutics. He is best known for his work at Amgen, where he served as Executive Vice President of Research and Development from 1990 to 2012.

During his tenure at Amgen, Reese played a pivotal role in the development and commercialization of several groundbreaking drugs, including Epogen (epoetin alfa), Neupogen (filgrastim), and Enbrel (etanercept). These drugs have had a profound impact on the lives of millions of patients worldwide, treating conditions such as anemia, neutropenia, and rheumatoid arthritis.

Reese is also recognized for his leadership in the field of biotechnology. He has served on the boards of several major biotechnology companies and has been a strong advocate for the industry's growth and development. He is a recipient of numerous awards and honors, including the Biotechnology Heritage Award from the Biotechnology Industry Organization (BIO).

Here is a table with some of David Reese's personal details and bio data:

David Reese is a visionary leader who has made significant contributions to the biotechnology industry. His work at Amgen has led to the development of life-changing drugs that have helped millions of patients worldwide.

David Reese Amgen

David Reese is a highly accomplished scientist and business leader who has made significant contributions to the biotechnology industry, particularly in the field of protein therapeutics. He is best known for his work at Amgen, where he served as Executive Vice President of Research and Development from 1990 to 2012.

• Research and Development
• Biotechnology
• Epogen
• Neupogen
• Enbrel
• Leadership

These key aspects highlight David Reese's expertise in research and development, his contributions to the biotechnology industry, and the groundbreaking drugs that he helped to develop. His work has had a profound impact on the lives of millions of patients worldwide, and he is recognized as a visionary leader in the field.

1. Research and Development

Research and development (R&D) is a critical component of the biotechnology industry, and David Reese has been a leading figure in this area throughout his career. At Amgen, he oversaw a team of scientists and researchers responsible for developing and commercializing some of the most groundbreaking drugs in the world, including Epogen, Neupogen, and Enbrel.

R&D is essential for the biotechnology industry because it allows companies to discover and develop new drugs and treatments for diseases. This is a complex and time-consuming process, but it is essential for improving the lives of patients and advancing the field of medicine. Reese has been a strong advocate for R&D, and his work at Amgen has helped to make the company a leader in the biotechnology industry.

One of the most important aspects of R&D is the ability to take basic research and translate it into new drugs and treatments. This requires a deep understanding of both science and business, and Reese has been able to successfully bridge the gap between these two worlds. He has also been a strong supporter of collaboration between academia and industry, which is essential for fostering innovation and bringing new drugs to market.

David Reese's contributions to R&D have had a profound impact on the biotechnology industry and the lives of millions of patients worldwide. He is a visionary leader who has helped to make Amgen one of the most successful biotechnology companies in the world.

2. Biotechnology

Biotechnology is the use of living organisms or their products to develop new drugs, treatments, and technologies. It is a rapidly growing field that has the potential to revolutionize the way we treat and prevent diseases.

David Reese is a leading figure in the biotechnology industry. He is the former Executive Vice President of Research and Development at Amgen, where he oversaw the development and commercialization of some of the most groundbreaking drugs in the world, including Epogen, Neupogen, and Enbrel.

Reese's work at Amgen has had a profound impact on the lives of millions of patients worldwide. Epogen is used to treat anemia, Neupogen is used to treat neutropenia, and Enbrel is used to treat rheumatoid arthritis. These drugs have helped to improve the quality of life for patients and have even saved lives.

Reese's success in the biotechnology industry is due in part to his deep understanding of both science and business. He is a strong advocate for collaboration between academia and industry, which is essential for fostering innovation and bringing new drugs to market.

The connection between biotechnology and David Reese is a powerful example of how science can be used to improve the lives of people around the world. Reese's work has helped to make Amgen one of the most successful biotechnology companies in the world, and his leadership has helped to advance the field of biotechnology as a whole.

3. Epogen

Epogen is a medication used to treat anemia, a condition in which the body does not have enough healthy red blood cells. It is a recombinant form of erythropoietin, a hormone that is produced by the kidneys and stimulates the bone marrow to produce red blood cells.

• Development and Approval
  

  Epogen was developed by Amgen and approved by the U.S. Food and Drug Administration (FDA) in 1989. It was the first biotechnology drug to be approved by the FDA.

• Role of David Reese
  

  David Reese was the Executive Vice President of Research and Development at Amgen when Epogen was developed. He played a key role in the drug's development and approval.

• Impact on Patients
  

  Epogen has had a profound impact on the lives of patients with anemia. Before Epogen was developed, many patients with anemia required regular blood transfusions. Epogen has allowed these patients to live more normal lives and has reduced their risk of complications from anemia.

• Advancements in Biotechnology
  

  The development of Epogen was a major advancement in biotechnology. It showed that it was possible to produce complex proteins using recombinant DNA technology. This has led to the development of many other biotechnology drugs that have improved the lives of patients around the world.

Epogen is a powerful example of how biotechnology can be used to improve the lives of patients. David Reese played a key role in the development of Epogen, and his work has had a profound impact on the field of biotechnology.

4. Neupogen

Neupogen is a medication used to treat neutropenia, a condition in which the body does not have enough healthy white blood cells. It is a recombinant form of granulocyte colony-stimulating factor (G-CSF), a hormone that is produced by the body and stimulates the bone marrow to produce white blood cells.

• Development and Approval
  

  Neupogen was developed by Amgen and approved by the U.S. Food and Drug Administration (FDA) in 1991. It was the second biotechnology drug to be approved by the FDA.

• Role of David Reese
  

  David Reese was the Executive Vice President of Research and Development at Amgen when Neupogen was developed. He played a key role in the drug's development and approval.

• Impact on Patients
  

  Neupogen has had a profound impact on the lives of patients with neutropenia. Before Neupogen was developed, many patients with neutropenia died from infections. Neupogen has allowed these patients to live more normal lives and has reduced their risk of death from infection.

• Advancements in Biotechnology
  

  The development of Neupogen was a major advancement in biotechnology. It showed that it was possible to produce complex proteins using recombinant DNA technology. This has led to the development of many other biotechnology drugs that have improved the lives of patients around the world.

Neupogen is a powerful example of how biotechnology can be used to improve the lives of patients. David Reese played a key role in the development of Neupogen, and his work has had a profound impact on the field of biotechnology.

5. Enbrel

Enbrel is a medication used to treat rheumatoid arthritis, a chronic inflammatory disease that affects the joints. It is a recombinant form of tumor necrosis factor (TNF) blocker, a protein that is involved in the inflammatory process.

David Reese was the Executive Vice President of Research and Development at Amgen when Enbrel was developed. He played a key role in the drug's development and approval.

Enbrel has had a profound impact on the lives of patients with rheumatoid arthritis. Before Enbrel was developed, there were few effective treatments for this disease. Enbrel has allowed patients to live more normal lives and has reduced their pain and disability.

The development of Enbrel was a major advancement in the treatment of rheumatoid arthritis. It showed that it was possible to use biotechnology to develop drugs that could target specific proteins involved in the disease process.

Enbrel is a powerful example of how biotechnology can be used to improve the lives of patients. David Reese played a key role in the development of Enbrel, and his work has had a profound impact on the field of biotechnology.

6. Leadership

David Reese is a highly accomplished scientist and business leader who has made significant contributions to the biotechnology industry. He is best known for his work at Amgen, where he served as Executive Vice President of Research and Development from 1990 to 2012.

Reese is a strong advocate for leadership in the biotechnology industry. He believes that leaders must have a deep understanding of both science and business in order to be successful. He also believes that leaders must be able to communicate effectively with a variety of stakeholders, including scientists, investors, and patients.

Reese's leadership has been instrumental in the success of Amgen. Under his leadership, Amgen has developed and commercialized some of the most groundbreaking drugs in the world, including Epogen, Neupogen, and Enbrel. These drugs have helped to improve the lives of millions of patients worldwide.

Reese's leadership has also been recognized by his peers. He has received numerous awards and honors, including the Biotechnology Heritage Award from the Biotechnology Industry Organization (BIO).

Reese's leadership is a model for others in the biotechnology industry. He has shown that it is possible to be a successful scientist and business leader. He has also shown that leadership is essential for the success of the biotechnology industry.

FAQs on David Reese Amgen

This section provides answers to frequently asked questions about David Reese and his work at Amgen.

Question 1: What was David Reese's role at Amgen?

Answer: David Reese was the Executive Vice President of Research and Development at Amgen from 1990 to 2012. In this role, he oversaw the development and commercialization of some of the most groundbreaking drugs in the world, including Epogen, Neupogen, and Enbrel.

Question 2: What are Epogen, Neupogen, and Enbrel used to treat?

Answer: Epogen is used to treat anemia, Neupogen is used to treat neutropenia, and Enbrel is used to treat rheumatoid arthritis.

Question 3: What is David Reese's leadership style?

Answer: David Reese is a strong advocate for leadership in the biotechnology industry. He believes that leaders must have a deep understanding of both science and business in order to be successful.

Question 4: What are some of the awards and honors that David Reese has received?

Answer: David Reese has received numerous awards and honors, including the Biotechnology Heritage Award from the Biotechnology Industry Organization (BIO).

Question 5: What is the significance of David Reese's work?

Answer: David Reese's work has had a profound impact on the biotechnology industry and the lives of millions of patients worldwide. He has helped to develop and commercialize some of the most groundbreaking drugs in the world, which have saved lives and improved the quality of life for patients.

This concludes our FAQs on David Reese Amgen. We hope this information has been helpful.

To learn more about David Reese and his work, please visit the following resources:

• David Reese's biography on Amgen's website
• David Reese's Biotechnology Heritage Award acceptance speech

Conclusion

David Reese is a highly accomplished scientist and business leader who has made significant contributions to the biotechnology industry. He is best known for his work at Amgen, where he served as Executive Vice President of Research and Development from 1990 to 2012.

During his tenure at Amgen, Reese played a pivotal role in the development and commercialization of several groundbreaking drugs, including Epogen, Neupogen, and Enbrel. These drugs have had a profound impact on the lives of millions of patients worldwide, treating conditions such as anemia, neutropenia, and rheumatoid arthritis.

Reese is also recognized for his leadership in the field of biotechnology. He has served on the boards of several major biotechnology companies and has been a strong advocate for the industry's growth and development. He is a recipient of numerous awards and honors, including the Biotechnology Heritage Award from the Biotechnology Industry Organization (BIO).

David Reese is a visionary leader who has made significant contributions to the biotechnology industry. His work has helped to improve the lives of millions of patients worldwide, and he is an inspiration to all who work in the field of biotechnology.